In Allergan USA v. MSN Labs, the US Court of Appeals for the Federal Circuit held, that later-filed, later-issued claims cannot serve as proper reference for invalidating earlier-filed, earlier-issued claims having the same...more
Pharmaceutical drug pricing and reimbursement remains a bipartisan focus as we draw closer to the November presidential elections, with politicians remaining steadfast in their efforts to turn up the heat on pharmaceutical...more
The PTAB Digest 2021/2022 provides an overview of PTAB statistics, trends, and updates that impact strategies and business decisions for patent owners and petitioners alike.
Significant developments included the...more
As of 2019, post-grant proceedings have been in use for seven years. Designed as an alternative to district court litigation, post-grant proceedings have offered litigants a faster and more cost-effective forum for resolving...more
EU – REGULATORY -
Brexit, Notified Bodies, and Medical Devices -
The House of Commons Library published a briefing paper on June 12 on the UK’s product standards and safety marking compliance in light of Brexit. In the...more
8/20/2019
/ Anti-Kickback Statute ,
Asia ,
China ,
Competition ,
Data Privacy ,
Drug Pricing ,
EU ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Life Sciences ,
Medical Devices ,
Patents ,
Pharmaceutical Industry ,
UK Brexit
A split panel of the US Court of Appeals for the Federal Circuit held on February 6 that claims to an assay for diagnosing myasthenia gravis are not patent eligible because they are directed to a natural law. The majority...more
UK authorities have recently released statements on how patents, trade marks, Community designs, and copyright will be handled if the United Kingdom and the European Union fail to reach a deal before Brexit....more
The UK government intends to ratify the Unitary Patent System and the Unified Patent Court prior to Brexit.
The Brexit referendum passed earlier this year in which the United Kingdom voted to leave the European Union...more
Pharmaceutical and agricultural companies in particular should consider the effect of Brexit on their European patent portfolios.
Supplementary Protection Certificates (SPCs) are governed by EU regulations and are thus...more
7/7/2016
/ Agricultural Sector ,
EU ,
Intellectual Property Protection ,
Member State ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Referendums ,
Supplementary Protection Certificate ,
UK ,
UK Brexit ,
UK Patent Act
Office changes rules for filing divisional applications so they are no longer time barred.
On October 18, the Administrative Council of the European Patent Office (EPO) announced that the 2010 amendments to Rule 36 of...more